Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752398 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 198
- Enrollment target
NCT03752398 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 198 participants.
The verdict
NCT03752398, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 198 participants
- Enrollment target
Study Summary
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.
Interventions
- BIOLOGICAL XmAb®23104
- BIOLOGICAL Yervoy® (ipilimumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03752398
The ClinicalTrials.gov registry entry for NCT03752398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which XmAb®23104 is the first listed.
NCT03752398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03752398 about?
NCT03752398 is a clinical study titled "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)". This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in sub...
What is the current status of trial NCT03752398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2019-05-01. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT03752398?
The interventions under investigation include: XmAb®23104 (BIOLOGICAL), Yervoy® (ipilimumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT03752398?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.